Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
Zymeworks BC Inc (NASDAQ: ZYME) closed the day trading at $11.23 up 0.09% from the previous closing price of $11.22. In other words, the price has increased by $0.09 from its previous closing price. On the day, 0.64 million shares were traded.
Ratios:
For a better understanding of ZYME, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.71 and its Current Ratio is at 4.71. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On December 16, 2024, JP Morgan Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $18.
Leerink Partners Upgraded its Market Perform to Outperform on November 07, 2024, whereas the target price for the stock was revised from $10 to $25.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 15 ’25 when EcoR1 Capital, LLC bought 49,502 shares for $11.43 per share. The transaction valued at 565,847 led to the insider holds 17,877,989 shares of the business.
EcoR1 Capital, LLC bought 5,919 shares of ZYME for $69,738 on May 19 ’25. The Director now owns 17,883,908 shares after completing the transaction at $11.78 per share. On Apr 16 ’25, another insider, EcoR1 Capital, LLC, who serves as the Director of the company, bought 73,953 shares for $11.16 each. As a result, the insider paid 825,589 and bolstered with 17,773,727 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 8.45 while its Price-to-Book (P/B) ratio in mrq is 2.42.
Stock Price History:
Over the past 52 weeks, ZYME has reached a high of $17.70, while it has fallen to a 52-week low of $8.21. The 50-Day Moving Average of the stock is -5.05%, while the 200-Day Moving Average is calculated to be -13.59%.
Shares Statistics:
A total of 69.58M shares are outstanding, with a floating share count of 67.74M. Insiders hold about 3.58% of the company’s shares, while institutions hold 101.25% stake in the company.
Earnings Estimates
Investors are keenly observing as 5.0 analysts analyze and rate the current performance of Zymeworks BC Inc (ZYME) in the stock market.The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.06 and low estimates of -$0.48.
Analysts are recommending an EPS of between -$1.01 and -$1.75 for the fiscal current year, implying an average EPS of -$1.42. EPS for the following year is -$1.44, with 7.0 analysts recommending between -$0.08 and -$2.04.
Revenue Estimates
6 analysts predict $18.38M in revenue for the current quarter. It ranges from a high estimate of $27M to a low estimate of $10.4M. As of the current estimate, Zymeworks BC Inc’s year-ago sales were $19.24MFor the next quarter, 6 analysts are estimating revenue of $28.75M. There is a high estimate of $51.8M for the next quarter, whereas the lowest estimate is $15.46M.
A total of 7 analysts have provided revenue estimates for ZYME’s current fiscal year. The highest revenue estimate was $141.1M, while the lowest revenue estimate was $81.42M, resulting in an average revenue estimate of $108.28M. In the same quarter a year ago, actual revenue was $76.3MBased on 8 analysts’ estimates, the company’s revenue will be $153.16M in the next fiscal year. The high estimate is $313.26M and the low estimate is $89.28M.
